[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2585246A1 - Procede d'obtention de formes pharmaceutiques solides a liberation prolongee - Google Patents

Procede d'obtention de formes pharmaceutiques solides a liberation prolongee Download PDF

Info

Publication number
FR2585246A1
FR2585246A1 FR8511575A FR8511575A FR2585246A1 FR 2585246 A1 FR2585246 A1 FR 2585246A1 FR 8511575 A FR8511575 A FR 8511575A FR 8511575 A FR8511575 A FR 8511575A FR 2585246 A1 FR2585246 A1 FR 2585246A1
Authority
FR
France
Prior art keywords
surfactant
anionic
solid pharmaceutical
pharmaceutical forms
hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR8511575A
Other languages
English (en)
Inventor
Rosa Martani
Elisabeth Le Huede
Jeanne Dumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortial SA
Original Assignee
Cortial SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortial SA filed Critical Cortial SA
Priority to FR8511575A priority Critical patent/FR2585246A1/fr
Priority to ZA865455A priority patent/ZA865455B/xx
Priority to DZ860158A priority patent/DZ964A1/fr
Priority to OA58909A priority patent/OA08368A/fr
Priority to CA000514590A priority patent/CA1304684C/fr
Priority to AT86305691T priority patent/ATE66599T1/de
Priority to EP86305691A priority patent/EP0214735B1/fr
Priority to ES8600570A priority patent/ES2000555A6/es
Priority to PT83052A priority patent/PT83052B/pt
Priority to DE8686305691T priority patent/DE3681099D1/de
Priority to AU60583/86A priority patent/AU585377B2/en
Priority to MA20973A priority patent/MA20745A1/fr
Publication of FR2585246A1 publication Critical patent/FR2585246A1/fr
Priority to US07/119,733 priority patent/US4834965A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE UN NOUVEAU PROCEDE D'OBTENTION DE FORMES PHARMACEUTIQUES SOLIDES A LIBERATION PROLONGEE CONSTITUEES PAR L'UTILISATION D'UN DERIVE HYDROPHILE ET D'UN TENSIO-ACTIF ANIONIQUE. CE PROCEDE MET EN OEUVRE L'EMPLOI SIMULTANE, AVEC LE PRINCIPE ACTIF, D'UN DERIVE HYDROPHILE ET D'UN TENSIO-ACTIF ANIONIQUE SULFONIQUE. LE COMPOSANT HYDROPHILE CONSTITUE UNE MATRICE QUI GONFLE AU CONTACT DE L'EAU; LE TENSIO-ACTIF FIXE LE PRINCIPE ACTIF POUR FORMER UN COMPLEXE PRINCIPE ACTIF-TENSIO ACTIF SOLUBLE DANS L'EAU A TOUS LES PH.

Description

1 2585246
La présente invention concerne un nouveau procédé d'obtention de formes pharmaceutiques solides à libération prolongée constituées par l'utilisation
d'un dérivé hydrophile et d'un tensio-actif anionique.
Plusieurs brevets ont déjà décrit de nombreux procédés associant un principe actif avec un composant hydrophile uniquement: brevets belge numéro 783.661, U.S.A. numéro 4.248.856, français numéros 84.18.208, 83. 13.268, 83.04.751, 82.18.407, 77.09.055, 76.30.362, 72.19.993. Mais leur application
est difficile pour des préparations à forte teneur en principe actif.
D'autres brevets mentionnent l'utilisation seule de tensio-actifs anioniques, ces agents intervenant uniquement pour faciliter la libération complète du principe actif (brevets français numéros 82.13.613, 82.04.672 et
77.23.022).
Nous avons trouvé maintenant un procédé permettant de réaliser des préparations galéniques solides à libération prolongée administrées par voie orale dont les cinétiques de dissolution peuvent être modulées à volonté et
utilisables dans tout le tractus digestif donc à des pH de 1,5 à 7,0.
Notre procédé met en oeuvre l'emploi simultané, avec le principe actif, d'un dérivé hydrophile et d'un tensio-actif anionique sulfonique. Le composant hydrophile constitue une matrice qui gonfle au contact de l'eau; le tensio-actif fixe le principe actif pour former un complexe principe
actif-tensio actif soluble dans l'eau à tous les pH.
Ce procédé intéresse tout principe actif cationique, soit très soluble, soit peu soluble dans l'eau. Il peut s'agir par exemple des sels de métoclopramide, de codéine, de dextrométhorphane, de quinine, de quinidine, de
morphine et de ses dérivés etc...
Notre étude a porté notamment sur le chlorydrate de métoclopramide, le phosphate de codéine, le chlorhydrate d'éthylmorphine, le sulfate de morphine, le bromhydrate de dextrométhorphane, le polygalacturonate de quinidine, le
sulfate de quinine.
Le dérivé hydrophile peut être une hydroxypropylméthylcellulose, une carboxyméthylcellulose sodique, une hydroxyéthylcellulose, une résine
synthétique comme le carbopol, un alginate de sodium etc...
Le tensio-actif anionique est le dioctyl sulfosuccinate de sodium. Il est
à remarquer que ce composé n'est pas résorbé par l'organisme.
Nous avons trouvé qu'en faisant varier les proportions de ces deux excipients, il est possible de moduler la cinétique de libération des principes actifs, tout en facilitant la technique de compression. En effet, l'agent hydrophile étant très volumineux, la présence du tensioactif permet
d'en diminuer la quantité.
14ZDOTP ap 2m ç ap aauasuld ua (% z Zueuuasgzda 2m o0ú) auuaeom uaT4uenb o0 aun.nod ZTos 4(ailTeTun amioj eT ap aleo4 assem VI ap % g zueuasatda 2m z) aso1n11aUIXugam1Xdo2dLxoxp2,P apue, odut 9 ulTzubnb aun mnod 4Tos saeçiiTmrs uoT nlossTp ap sanb zuTD sap zuaToqo uos anb uaTq ailuow Fnb sazde-To I aqoueld wI aed sgzlsnTiI luos nualqel aD ap slzllnsal sao asolnlIaolllqmlXdo.d1<xojp&H: j -mnTpos ap azeuTmDnsojlns lzzoTq: V Ei % C8 i 0i Z 8 i H8 I i----------------- i----------------i i----I i Z IL i Z 69 I % OL i H9 i --- -- --- --- t - - - - --------i-- ------- -----___ ---; I % ú9 i % 19 I % 8'19 i Ht i i-------- i- ------- i-................
..i1..DTD: _____________-;----- - ---------;- ------- i----
i-----__-__--;_- I------- - i----i I %1I i % H1 iI i
à ààà-;_..-----_ - __ _;_ _ _ __ _ _ _
Sm L v i i zm Oú R Vm ç v 2Im 0 V i s1 S:uaT.dTzixe Xnap sep suo-îziodozd ap SUO TJ:t.TA */I (61 ou agdou:euldoia alou) aluvuinol allaled eI Q aSal ap alIaTPaT;o apoqlom nI led sanualqo uoTlnlossrp ap sanbTlguTD apTme. dolDoOgm ap aleip&qlolqo np aldmaxz 01 *Hd np sazuepuadapuT zuos uoFle1aqTl ap sanbTzuTo sel 'aino uâ ÀasTid ap qTun jed 2m O oQ I ap zurlnu;Tze-oTsuae ap avTzuvnb aun Oam '% oç e 01 ap IaTaeA inad s9uaTdToxa xnap sep itoz a2aeuaomnod au ÀuoTznlossTp ap sanbTzutD ç saluaalg;yp suoualqo snou 'allqdoapXq aTip ap luelsuoz xnel un mnod mnTpos ap azruT3onsojlns 143oTP op xnev slI îaae A zuesTev ue 'sanalITe 1ea alqeToaaddr a2eluene un aluasaidai -jaz '(alTelTun olnmuoj el op % O8 inbsnP) aluelziodurmT lTuenb ua lsa jtlos adTouTld al no seo sal suea 9MZS8Sz I i1 i 2m SI -i Àagpavolat lsa uoT-nlossTp ap enbpauTzD el snld luvzaoumc zsa s Tze-oJsua4 ua xnev el snId 'alTqdoopXq 9 ATztap ua U uezSUOo xnfl un JaAs axBT/lun elnmo0 -el SuBp mnTpos ap oauTzfnsojIns IXIoTp ep xne np uoji:uoj ua sanbT:IguTa sap UOazA el au9pjap ua uaeq lam 0O Tnb soade-To II eqzueId el xed siznsnIIT juos nuelqu a zap szuinsaa sae :solnliol gqalido:dXxoapH: Àmnypos ap ateuTr nsojlns Iúz:oTI i % E9 i % L i % 08 i % 68; % 6 i % L6 i H8 i i _______;------------i i-- ----- ------i--------- i--------- i---- i I % I I % 99 i% 69 i % LL i % ú8 i Z 16 i H9 i ---.........-- - -i-.........i.I-.------___- j _ _ i % 8ú i % 95 i % 19 i % Z9 i % OL i % SL i HR i
-- - -- - -............i i-- - - -.........I.........;.....I----....
i % Z i I % 67 i TI i % i % Z9 i % 69 i Hú i i- _______..-I........._---------_I--------- i--------- i--- - i-.... i i % Z i % SE i % i % 9 i % i % Z9 i HZ i T I % 8i i % 9Z i % úú i % 98 i % E % TI i Hl i i;mOu 2mg'izismoú smçz;'9gi;moú gmGsimoú 2miu imog 8mz;imoe 2moi i ' Vi i i V i i V i - - V i î Fi oT i (9) i (S) i (i) i (0 i (Z) i (T) i
-- - --à -- - - ---à - - --- à -.---- --à-- - --à-- - -- -à- -
Àal qdoipzfq 9AT1ap ap zUusUOz xnUU un Unod JT:Iu-OTsuai ap xnfl np SUOeTiUA /z g ÀanbTuojIns _Tlau-oTsuez np uamaInas 2m ç'L ap aDuasaJd ue (aUzT.un amio ul ap % i'4I zueuesga:dea 2m 81) alqT.z sa:l 9,.p-uBnb aun mrod:os 'mnTpos ap azruTDunsojlns c slual dloxa xnap sep uolliodold ap suoTzt7inA sel 4a 3T-:o-oTsuel ap xnel np suoTzlTJiA seT 'Hd op suollz1eA sel uuluao8uov saesurTmTs sl2llnsa[ sap auuop lUO Z uo:eilnmao; ap d1l aumui el suep sa;lluT 'se;Tn43 sBadTou'Td sazlne sea uasmamalxa Huos e ZTos 'S'l Rd *III eqoueld el ad silzsnllu luos slelilnsai se-1 saursToa sanuazqo uotlnlosslp op senblzouTo seI 6'9 Rd l0os ''s HRd apTos natIFm ua 1tos 'Hd ap lueTpeag ua rios 'luewido ug i g 8 i %6L i g ZS i Z0 i 9 H8I1 I---------------- ----------------i---------------- ------------- --- i I % 69 i % L9 I Z TIL i %69 i H9 1
i - --i i---- i --
i %8g i X 9 I z T9 i % 19 I H? I -- - - -- - - - i-- - - -- - - -- - - --- -................- i----.I i i i i................i He-i i %Z7 i %Q 9 iiI H: i ? i gúj? i HZ i i i X Oú i i 1- H i i à à i......:- t i ài 6'9 Hd (M) f HRd () S'T Hd (z) i i Hd ap luaTpeU2 (I) ST or S i i Hd szua.i; Fp Q uolntossTp ap sanbjlujD sep apn%2 /E j? i I i i i i
2585246

Claims (4)

REVENDICATIONS
1 - Procédé d'obtention de formes pharmaceutiques solides à libération prolongée d'un principe actif cationique caractérisé par le fait qu'il met en oeuvre simultanément un dérivé hydrophile et un tensio-actif anionique formant
un complexe soluble à tous les pH.
2 - Procédé d'obtention selon la revendication 1 caractérisé par le fait qu'en faisant varier les proportions du dérivé hydrophile et du tensioactif
anionique, on peut maltriser la technique de compression.
3 - Procédé d'obtention selon la revendication 1 caractérisé par le fait qu'en faisant varier les proportions du dérivé hydrophile et du tensioactif
anionique, on peut modifier la cinétique de libération des principes actifs.
4 - Procédé d'obtention selon la revendication 1 caractérisé par le fait que le pourcentage total des deux excipients (composé hydrophile et tensio-actif anionique) est compris entre 10 et 50 % et la quantité du
tensio-actif est comprise entre 1 et 30 mg par unité de prise.
FR8511575A 1985-07-26 1985-07-26 Procede d'obtention de formes pharmaceutiques solides a liberation prolongee Pending FR2585246A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR8511575A FR2585246A1 (fr) 1985-07-26 1985-07-26 Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
ZA865455A ZA865455B (en) 1985-07-26 1986-07-22 Controlled release pharamceutical composition
DZ860158A DZ964A1 (fr) 1985-07-26 1986-07-23 Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée.
ES8600570A ES2000555A6 (es) 1985-07-26 1986-07-24 Procedimiento para la preparacion de una forma de dosificacion de unidad farmaceutica solida de liberacion controlada
CA000514590A CA1304684C (fr) 1985-07-26 1986-07-24 Composition pharmaceutique a liberation reglee
AT86305691T ATE66599T1 (de) 1985-07-26 1986-07-24 Arzneimittel mit gesteuerter freigabe.
EP86305691A EP0214735B1 (fr) 1985-07-26 1986-07-24 Composition pharmaceutique à libération commandée
OA58909A OA08368A (fr) 1985-07-26 1986-07-24 Procédé d'obtention de formes pharmaceutiques solides à libération prolongée.
PT83052A PT83052B (pt) 1985-07-26 1986-07-24 Processo para a preparacao de composicoes farmaceuticas de libertacao controlada a base de um sal de adicao de acido ou de amonio quaternario, de um polimero e de um agente tensio-activo
DE8686305691T DE3681099D1 (de) 1985-07-26 1986-07-24 Arzneimittel mit gesteuerter freigabe.
AU60583/86A AU585377B2 (en) 1985-07-26 1986-07-25 Controlled release pharmaceutical composition
MA20973A MA20745A1 (fr) 1985-07-26 1986-07-25 Procede d'obtention de formes solides a liberation prolongee
US07/119,733 US4834965A (en) 1985-07-26 1987-11-12 Controlled release pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8511575A FR2585246A1 (fr) 1985-07-26 1985-07-26 Procede d'obtention de formes pharmaceutiques solides a liberation prolongee

Publications (1)

Publication Number Publication Date
FR2585246A1 true FR2585246A1 (fr) 1987-01-30

Family

ID=9321740

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8511575A Pending FR2585246A1 (fr) 1985-07-26 1985-07-26 Procede d'obtention de formes pharmaceutiques solides a liberation prolongee

Country Status (13)

Country Link
US (1) US4834965A (fr)
EP (1) EP0214735B1 (fr)
AT (1) ATE66599T1 (fr)
AU (1) AU585377B2 (fr)
CA (1) CA1304684C (fr)
DE (1) DE3681099D1 (fr)
DZ (1) DZ964A1 (fr)
ES (1) ES2000555A6 (fr)
FR (1) FR2585246A1 (fr)
MA (1) MA20745A1 (fr)
OA (1) OA08368A (fr)
PT (1) PT83052B (fr)
ZA (1) ZA865455B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058111T3 (es) * 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
DK175591B1 (da) * 1987-10-16 2004-12-13 Elan Corp Plc Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf
WO1989009066A1 (fr) * 1988-03-24 1989-10-05 Bukh Meditec A/S Composition a diffusion regulee
FR2630913A1 (fr) * 1988-05-09 1989-11-10 Delalande Sa Comprimes de sel(s) hydrosoluble(s) de diltiazem a liberation programmee et leur procede de fabrication
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions
ATE154238T1 (de) * 1992-02-20 1997-06-15 Euro Celtique Sa Arzneimittel verzögerter wirkstoffabgabe
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5932248A (en) * 1993-11-18 1999-08-03 Paragon Medical Limited Controlled release preparations for cytotoxic or cytostatic drugs
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
WO1997037680A1 (fr) * 1996-04-05 1997-10-16 The Board Of Trustees Of The University Of Illinois Complexes macromoleculaires pour administration de medicaments
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
RU2241458C2 (ru) * 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DK2092936T3 (da) * 2000-02-08 2013-06-17 Euro Celtique Sa Orale opioid-agonist-formuleringer sikret mod forfalskning
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
PT1414451E (pt) 2001-08-06 2009-07-31 Euro Celtique Sa Formulações agonistas de opióides com antagonista libertável e sequestrado
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE20321531U1 (de) 2002-04-05 2007-11-22 Euro-Celtique S.A. Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfaßt
CA2498798A1 (fr) * 2002-09-20 2004-04-01 Alpharma, Inc. Formulation opioides a liberation prolongee et procedes d'utilisation connexes
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
BRPI0417106A (pt) * 2003-12-18 2007-02-06 Huntsman Spec Chem Corp granulos de pesticida com surfactante melhorado de soltura rápida
CN101014331A (zh) 2004-04-27 2007-08-08 美迪诺亚公司 苯氧烷羧酸衍生物在治疗炎症中的应用
KR100753984B1 (ko) * 2004-05-14 2007-08-31 강원대학교산학협력단 우회전성 모르피난의 신경보호적 특성
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
ES2531735T3 (es) * 2004-10-15 2015-03-18 Supernus Pharmaceuticals, Inc. Preparaciones farmacéuticas con menor potencial de abuso
EP1702558A1 (fr) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
WO2006119389A2 (fr) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Preparations de quinine
WO2007056205A2 (fr) * 2005-11-04 2007-05-18 Eastman Chemical Company Esters de carboxyalkylcellulose pour administration d'agents pharmaceutiquement actifs peu solubles
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
KR20150029762A (ko) 2006-06-19 2015-03-18 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
US8362029B2 (en) * 2008-12-31 2013-01-29 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
BR112012008317A2 (pt) 2009-09-17 2016-03-22 Upsher Smith Lab Inc produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
MX2016000810A (es) 2013-07-23 2016-08-05 Euro Celtique Sa Combinacion de oxicodona y naloxona para su uso en el tratamiento de dolor en pacientes que sufren de dolor y una enfermedad que resulta la disbiosis intestinal y/o aumento del riesgo de la translocacion bacteriana intestinal.
US20150031769A1 (en) 2013-07-25 2015-01-29 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
CA2931547A1 (fr) 2013-12-09 2015-06-18 Durect Corporation Complexes de principes pharmaceutiquement actifs, complexes de polymeres, et compositions et procedes les impliquant
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
CN106470678A (zh) 2014-06-02 2017-03-01 美迪诺亚公司 抑制或治疗纤维化的方法
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
BR112017010700A2 (pt) 2014-11-26 2018-05-08 Medicinova Inc combinação de ibudilaste e riluzol e métodos de uso da mesma
EP3364955B1 (fr) 2015-10-09 2022-04-20 RB Health (US) LLC Formulation pharmaceutique
EP3544614A4 (fr) 2016-11-28 2020-08-05 Lipocine Inc. Traitement oral à base d'undécanoate de testostérone
AU2019308326A1 (en) 2018-07-20 2021-03-18 Lipocine Inc. Liver disease
US20220387364A1 (en) 2021-05-28 2022-12-08 Medicinova, Inc. Methods to decrease triglyceride synthesis in the liver

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2523446A1 (fr) * 1982-03-19 1983-09-23 Dietlin Francois Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2802114A1 (de) * 1978-01-19 1979-07-26 Sandoz Ag Neue pharmazeutische zusammensetzung und verfahren zu deren herstellung
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2523446A1 (fr) * 1982-03-19 1983-09-23 Dietlin Francois Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 100, no. 18, avril 1984, page 358, réf. no. 144916j, Columbus, Ohio, US; P.B. DALY et al.: "The effect of anionic surfactants on the release of chlorpheniramine from a polymer matrix tablet" & INT. J. PHARM. 1984, 18(1-2), 201-5 *

Also Published As

Publication number Publication date
US4834965A (en) 1989-05-30
DE3681099D1 (de) 1991-10-02
PT83052B (pt) 1988-07-01
ZA865455B (en) 1987-03-25
PT83052A (en) 1986-08-01
EP0214735A1 (fr) 1987-03-18
DZ964A1 (fr) 2004-09-13
AU6058386A (en) 1987-01-29
MA20745A1 (fr) 1987-04-01
OA08368A (fr) 1988-02-29
ATE66599T1 (de) 1991-09-15
CA1304684C (fr) 1992-07-07
ES2000555A6 (es) 1988-03-01
AU585377B2 (en) 1989-06-15
EP0214735B1 (fr) 1991-08-28

Similar Documents

Publication Publication Date Title
FR2585246A1 (fr) Procede d&#39;obtention de formes pharmaceutiques solides a liberation prolongee
ES2313739T3 (es) Farmacos antitusigeno administrados por medio de resinas de intercambio ionico.
KR950006219B1 (ko) 전신 작용을 나타내는 경구적 치료 시스템
EP1007005B1 (fr) Compositions pharmaceutiques pour la liberation controlee de substances actives
EP0385846B1 (fr) Composition pharmaceutique à libération prolongée d&#39;acide valproîque
US8425938B2 (en) Pharmaceutical composition
FI87045B (fi) Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart.
USRE34990E (en) Oral therapeutic system having systemic action
JPS61151125A (ja) ジヒドロコデイン／イブプロフエン薬剤組成物及び方法
US20070036843A1 (en) Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
US4540685A (en) Process for the production of readily soluble 5-aminosalicylic acid preparations, compositions and methods of use
JPH05279247A (ja) 徐放性液剤
KR19990087084A (ko) 이부프로펜 투여형
CA2802093A1 (fr) Therapie de combinaison avec de la lisdexamphetamine et la guanfacine a liberation prolongee
EP0349453A1 (fr) Nouvelle forme pharmaceutique à libération prolongée à base d&#39;un complexe résine-principe actif
FR2735369A1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
KR900011451A (ko) 새로운 의약품 제제
JP4808405B2 (ja) 高度に水溶性の電解質薬剤のための水性徐放性ドラッグデリバリーシステム
BE1001706A3 (fr) Forme d&#39;administration solide, a desagregation rapide, du diclofenac.
US20060018972A1 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
FR2576213A1 (fr) Nouveau procede d&#39;obtention de formes pharmaceutiques a liberation prolongee
TWI729039B (zh) 用於預防及治療眼疼痛之氨基膦衍生物
RU2635185C2 (ru) Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
DE602004009414T2 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo-[2.2.1]heptan-2-amin
EP0471718A1 (fr) Composition pharmaceutique a base de paracetamol.